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BACKGROUND: This retrospective study aimed to identify prognostic factors in patients with brain metastases from cutaneous
melanoma.
METHODS: In all, 265 patients under regular screening according to valid national surveillance guidelines were included in the study.
Kaplan–Meier analyses were performed to estimate and to compare overall survival. Cox modeling was used to identify independent
determinants of the overall survival, which were used in explorative classification and regression tree analysis to define meaningful
prognostic groups.
RESULTS: In total, 55.5% of our patients presented with two or less brain metastases, 82.6% had concurrent extracranial metastasis and
64% were asymptomatic and diagnosed during surveillance scans. In all, 36.7% were candidates for local treatment (neurosurgery or
stereotactic radiosurgery (SRS)). The median overall survival of the entire collective was 5.0 months (95% confidence interval:
4.3–5.7). Favourable independent prognostic factors were: normal pre-treatment level of serum lactate dehydrogenase (Po0.001),
administered therapy (neurosurgery or SRS vs other, P¼0.002), number of brain metastases (single vs multiple, P¼0.032) and
presence of bone metastasis (false vs true, P¼0.044). Three prognostic groups with significantly different overall survival were
identified. Candidates for local treatment (group I) had the longer median survival (9 months). Remaining patients could be further
classified in two groups on the basis of serum lactate dehydrogenase.
CONCLUSION: Applied treatment and serum lactate dehydrogenase levels were independent predictors of survival of patients with
brain metastases from cutaneous melanoma. Patients receiving local therapy have overall survival comparable with general stage IV
melanoma patients.
British Journal of Cancer (2010) 102, 1213–1218. doi:10.1038/sj.bjc.6605622 www.bjcancer.com
Published online 6 April 2010
& 2010 Cancer Research UK
Keywords: brain metastasis; cutaneous melanoma; survival; stereotactic radiosurgery; neurosurgery; serum lactate dehydrogenase
                                                               
Cutaneous melanoma is one of the most common causes of
cerebral metastasis (Zimm et al, 1981; Nussbaum et al, 1996).
Large clinical series show that brain metastases are diagnosed in
up to 10% of melanoma patients during their lifetime and autopsy
data show that up to 73% of patients who die from disseminated
cutaneous melanoma have brain involvement (de la Monte et al,
1983; Sampson et al, 1998). Cerebral metastasis is a very
distressing event in the natural course of melanoma because it
carries the worst prognosis of all visceral metastases and
represents a major cause of death in patients with disseminated
disease (Brand et al, 1997).
Current management of cerebral metastasis depends largely on
the number and the size of lesions and on the extracranial
extension of metastatic disease. It involves neurosurgery, stereo-
tactic radiosurgery (SRS), whole brain radiation therapy (WBRT)
and chemotherapy. Neurosurgery is usually offered to patients
with single or a few metastatic lesions, provided that brain
metastases are surgically accessible and that the patient can
tolerate the operation. Stereotactic radiosurgery is offered as an
alternative to direct neurosurgery in patients with a few brain
metastases, which cannot be surgically removed and WBRT is used
in conjuction with the neurosurgery or SRS because it is associated
with better local control (Eichler and Loeffler, 2007). Such
intervention can provide effective palliation and prolong life
significantly. Patients not eligible for surgery or SRS are usually
offered WBRT alone or combined with chemotherapy depending
on the presence of active systemic disease (Morris et al, 2004).
Those with poor Karnofsky performance score (KPS) may
be managed with steroids and other supportive measures.
Generally accepted standards for the application of different
treatment modalities in patients with brain metastases from
melanoma do not exist so far (Douglas and Margolin, 2002;
McWilliams et al, 2003).
The aim of this retrospective study was to analyse prognostic
factors, effects of treatment and survival outcome of relatively
Received 29 January 2010; revised 15 February 2010; accepted 3 March
2010; published online 6 April 2010
*Correspondence: Dr C Garbe. E-mail: claus.garbe@med.uni-tuebingen.de
British Journal of Cancer (2010) 102, 1213–1218
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
snon-selected patients with melanoma metastatic to the brain to
identify meaningful prognostic groups with respect to overall survival.
PATIENTS AND METHODS
From October 1986 until March 2003, 265 cutaneous melanoma
patients were diagnosed with cerebral metastasis in the University
Medical Center of Tuebingen in Southern Germany. Systemic
screening and staging algorithms according to valid national
surveillance guidelines were used (Orfanos et al, 1994; Garbe et al,
2006). These algorithms consider the individual risk of relapses for
each patient. Prognostic factors include, for example, tumour
thickness according to Breslow and the development of previous
metastases. Recently, a surveillance programme for stage I–IV
patients is used; for example, stage III patients are staged once a
year via a computerised tomography (CT)-scan. Stage II patients
are followed-up via clinical inspections, lymph node ultrasound
and the evaluation of the tumour marker S-100.
Clinical and pathological data on these patients were obtained
from the electronic database of the Central Malignant Melanoma
Registry, which is a hospital-based registry (Garbe et al, 2000;
Lasithiotakis et al, 2007). In addition, medical records were
reviewed to obtain details from operative, pathological and
radiation therapy reports. All received data were recorded with
standardised forms and finally computerised. The following
information was obtained: demographics, anatomical localisation
and histological characteristics of primary melanoma, time interval
between diagnoses of primary melanoma and brain metastases,
site of primary cutaneous melanoma, clinical presentation of brain
metastases, localisation of brain metastases, number and size of
brain metastases; number and location of other melanoma
metastases, KPS, serum lactate dehydrogenase at time of
presentation of brain metastases, administered treatment, response
to treatment, date of death or last follow-up and cause of death.
Diagnosis of brain metastases was mainly based on magnetic
resonance imaging (MRI). In a few cases that were diagnosed
during the earlier years of the study, CT was used instead. No
specific treatment protocol was used. Usually, patients were
offered surgery if they had a single or a few surgically accessible
brain metastases and a good KPS. If, brain metastases was difficult
to access surgically SRS was offered instead. Only 10 out of 94
patients treated with surgery or SRS had more than two brain
metastases (eight surgery and two SRS). In these cases, decision
was based on clinical experience. Treatment with SRS was
delivered using a linear accelerator in all cases. Patients, who
received WBRT, were usually treated with a total dose of 30Gy
with a fractionation of 2Gy (5 days a week for 3 weeks). Tumour
response was evaluated using CT and/or MRI every 3 months after
therapy. Response to treatment was described using the RECIST
criteria (Therasse et al, 2000).
Statistical analysis
Follow-up time was defined as the date of last follow-up or death
minus date of diagnosis of brain metastases (overall survival).
Brain metastasis diagnosed within 30 days of diagnosis of the
primary melanoma was considered synchronous. Survival was
calculated from the date of diagnosis of brain metastases. Follow-
up time was described as a median value with interquartile range
(IQR). Only deaths caused by melanoma were considered in
survival analysis. Melanoma-specific survival curves and estimated
median survival with relative 95% confidence intervals (95% CIs)
were generated according to the Kaplan–Meier product-limit
method and were compared by the two-sided log-rank test.
Variables proven significant in the univariate analyses at the 0.2
level were included in a Cox proportional hazards model. As
radiological response mainly depends on the administered
therapy, we excluded the variable ‘response to therapy’ from
multivariate analysis to have a better insight to the influence of the
indication for treatment on overall survival. Age was entered in the
multivariate analysis as continuous variables. Categorical variables
were dummy-coded and P-values were based on the Wald test. We
examined the graphic plot of the log–log survivor function for the
variables entered in the analysis. No violation of the proportional
hazards assumption was found. Explorative classification and
regression tree analysis (CRT) was used to define meaningful
prognostic groups with respect to survival probability using
information gained from Cox modeling regarding the independent
prognostic factors. Minimum size of parental and child nodes were
defined as 50 and 20 participants, respectively. Final groups of
CRT analysis were presented with median survival time (months)
and approximate 95% confidence intervals. Kaplan–Meier curves
for the final prognostic groups were generated and compared
pairwise by means of log-rank test. Throughout the analysis, two-
sided P-values o0.05 were considered statistically significant. All
statistical analyses were performed using the Statistical Package for
Social Sciences (SPSS) version 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 265 patients with cerebral metastasis because of
cutaneous melanoma were included in our analysis. The clinical
and pathological characteristics of these patients are presented in
Table 1. There were 154 men (58.1%) and 111 women (41.9%). The
median age at the time of diagnosis of brain metastasis was 58
years (IQR: 22) and did not differ significantly between men and
women (P¼0.076). Cerebral metastases were present at initial
diagnosis of the primary melanoma in 14 patients (5.3%). Eight
patients (3.0%) had an unknown primary lesion. In these patients,
the diagnosis of melanoma was based on histological examination
of excised metastases. Forty-six patients (17.4%) presented with
brain metastases without other systemic metastasis. However, a
significant proportion of patients (82.3%) suffered from metastatic
disease to organs other than the brain. Six patients (2.2%)
developed brain metastases directly from stage I, 28 (10.6%) from
stage II and 62 (23.4%) from stage III. The rest of the patients were
diagnosed with already present stage IV disease.
The most common extracerebral sites of metastasis were lung
(62.6%), liver (38.9%) and distant skin/soft tissue (37.4%).
Approximately, half of the patients (55.6%) had single or two
brain metastases as determined by CT or MRI. Ninety-six patients
(36.2%) complained of symptoms associated with brain metastases
(i.e., headaches, seizures, palsy) that led to the diagnosis of the
disease because of the performance of brain scans. The other 64%
were asymptomatic and diagnosed during surveillance.
In all, 128 patients (48.3%) had undergone systemic therapy
(chemotherapy or interferon) before the diagnosis of the brain
metastases. On the diagnosis of cerebral metastasis a therapy was
initiated for 256 (96.6%) patients. Nine patients (3.4%) died before
the initiation of any treatment.
We identified 12 different therapy combinations applied (data
not shown). Therefore, we created five hierarchical therapy groups
in the following order: neurosurgical operation ranked first
followed by SRS, WBRT, systemic chemotherapy and finally the
group that received no treatment. Patients who underwent
neurosurgical resection or SRS were classified in OP or SRS
group, respectively, regardless of other therapies administered
(i.e., WBRT or chemotherapy). Patients who did not undergo
neurosurgical operation or SRS but who underwent WBRT were
classified as WBRT regardless of additional chemotherapy.
Patients treated with systemic chemotherapy without surgery,
SRS or WBRT comprised the ‘systemic chemotherapy’ group.
Patients receiving no treatment or only corticosteroids were
classified as ‘no therapy’. The distribution of the patients in the
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streatment groups according to the aforementioned definitions is
presented in Table 1. In total, 63 patients (23.8%) underwent
neurosurgery (group OP), 31 (11.7%) were treated with SRS, 122
(46.0%) comprised the WBRT group and 22 patients (8.3%) were
administered systemic chemotherapy. The remaining 12 patients
(4.5%) were classified in the ‘no therapy group’.
During follow-up, 253 (95.5%) of the patients succumbed to
their disease. The median overall survival of all 265 patients was 5
months (95% CI: 4.3–5.7). All patients except for one died because
of melanoma. Therefore, disease-specific survival should be
identical with the overall survival of our cohort. In the univariate
survival analysis, age at the time of diagnosis of brain metastases
(P¼0.004), number of brain metastases (Po0.001), localisation of
brain metastases (supra-, infratentorial) (Po0.001), meningeal
disease (P¼0.002), serum lactate dehydrogenase level (Po0.001),
Table 1 Patients and brain metastasis characteristics
Patients
N (%)
Median survival
months
(95% CI) P
a
Gender
Male 154 (58.1) 5.0 (4.0–6.0) 0.100
Female 111 (41.9) 5.0 (3.8–6.2)
Age
b
o45years 68 (25.7) 7.0 (5.4–8.6) 0.004
444years 197 (74.3) 4.0 (3.2–4.8)
AJCC stage of primary melanoma
I 66 (24.9) 5.0 (4.0–6.0) 0.500
II 82 (30.9) 5.0 (4.0–6.0)
III 67 (25.3) 4.0 (3.4–4.6)
IV 31 (11.7) 5.0 (3.0–7.0)
Unknown 19 (7.2)
Distant disease free interval
o24 months 133 (50.2) 4.0 (3.1–4.9) 0.003
X24 months 132 (49.8) 6.0 (5.0–7.0)
Brain metastasis free interval
o24 months 113 (42.6) 4.0 (3.1–4.9) 0.015
X24 months 152 (57.4) 6.0 (5.0–7.0)
Symptomatic brain metastasis
b
Yes 96 (36.2) 4.0 (2.5–5.5) 0.120
No 147 (55.5) 5.0 (4.1–5.9)
Unknown 22 (8.3)
Number of brain metastases
b
1 107 (40.4) 8.0 (6.3–9.7) o0.001
2 40 (15.1) 5.0 (3.7–6.3)
Multiple 118 (44.5) 3.0 (2.2–3.8)
Localization of brain metastases
b
Supratentorial 191 (72.1) 6.0 (5.2–6.9) o0.001
Infratentorial 16 (6.0) 4.0 (4.2–5.8)
Both 43 (16.2) 2.0 (1.2–2.8)
Unknown 15 (5.7)
Meningeal disease
Yes 6 (2.3) 2.0 (1.4–2.6) 0.002
No 259 (97.7) 5.0 (4.2–9.0)
Diameter of largest brain metastases
b
p15mm 124 (46.8) 6.0 (4.5–7.5) 0.088
415mm 91 (34.3) 5.0 (4.2–5.8)
Unknown 50 (18.9)
LDH
b
Normal range 100 (37.7) 7.0 (6.0–8.1) o0.001
 1–2 times maximum
normal values
72 (27.2) 3.0 (2.2–3.8)
4 2 times maximum normal
values
23 (8.7) 1.0 (0.3–1.7)
Unknown 70 (26.4)
Karnofsky performance score
b
480% 168 (63.4) 6.0 (5.0–7.0) o0.001
p80% 86 (32.4) 3.0 (2.4–3.6)
Unknown 11 (4.2)
Number of extracerebral metastasis sites
b
0 46 (17.4) 7.0 (5.1–8.9) o0.001
1 45 (17.0) 7.0 (5.2–8.9)
2 62 (23.4) 4.0 (2.9–5.1)
3 48 (18.1) 3.0 (1.1–4.9)
X4 64 (24.2) 3.0 (2.0–4.0)
Table 1 (Continued)
Patients
N (%)
Median survival
months
(95% CI) P
a
Presence of locoregional metastasis
b
Yes 178 (67.2) 4.0 (3.1–4.9) 0.156
No 87 (32.8) 6.0 (5.1–7.0)
Presence of distant lymph node metastasis
b
Yes 96 (36.2) 3.0 (2.0–4.0) 0.006
No 169 (63.8) 5.0 (4.1–6.0)
Presence of distant skin/soft tissue metastasis
b
Yes 99 (37.4) 3.0 (2.0–4.0) 0.016
No 166 (62.6) 5.0 (4.2–5.8)
Presence of lung metastasis
b
Yes 166 (62.6) 5.0 (4.2–5.8) 0.121
No 99 (37.4) 5.0 (3.5–6.5)
Presence of liver metastasis
b
Yes 103 (38.9) 3.0 (2.0–4.0) o0.001
No 162 (61.1) 6.0 (5.1–6.9)
Presence of bone metastasis
b
Yes 41 (15.5) 3.0 (2.2–3.8) 0.001
No 224 (84.5) 5.0 (4.1–5.9)
Presence of adrenal gland metastasis
b
Yes 32 (12.1) 4.0 (1.3–6.7) 0.126
No 233 (83.9) 5.0 (4.2–5.8)
Presence of spleen metastasis
b
Yes 29 (10.9) 4.0 (1.4–6.6) 0.400
No 236 (89.1) 5.0 (4.1–5.9)
RTOG Classes
Class I 29 (11.9) 9.0 (7.0–15.0) o0.001
Class II 180 (67.9) 5.0 (4.0–6.0)
Class III 56 (21.3) 2.0 (2.0–3.0)
Administered therapy
Neurosurgical operation 63 (24.6) 9.0 (7.0–11.0) o0.001
SRS 31 (12.1) 9.0 (7.0–11.1)
WBRT 122 (47.7) 4.0 (3.2–4.8)
Chemotherapy 28 (10.9) 3.0 (1.6–4.4)
No therapy 12 (4.7) 1.0 (0.1–1.9)
Neurosurgical operation or SRS 94 (36.7) 9.0 (8.0–11.0) o0.001
WBRT 122 (47.7) 4.0 (3.2–4.8)
Abbreviations: AJCC¼American Joint Commission on Cancer; BM¼brain metas-
tasis; LDH¼serum lactate dehydrogenase; RTOG¼Radiation Therapy Oncology
Group; SRS¼stereotactic radiosurgery; WBRT¼whole brain radiation therapy.
aLog-rank test.
bAt the time of diagnosis of the brain metastasis.
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(Po0.001), presence of liver (Po0.001), bone (P¼0.001), distant
lymph node (P¼0.006), distant skin/soft tissue metastasis
(P¼0.016), classification according to the RTOG classes (Gaspar
et al, 1997) (Po0.001) as well as type of treatment (Po0.001) and
response to treatment (Po0.001) were significantly associated with
the overall survival (Table 1). Women had slightly longer overall
survival as compared with men but this difference did not reach
statistical significance (P¼0.100). Similarly, diameter of largest
brain metastasis larger than 15mm, presence of symptoms related
to brain metastases, presence of adrenal gland, spleen or
locoregional metastases were associated with shorter median
survival without reaching statistical significance (P40.05 for each
variable) (Table 1). Presence of lung metastasis at the time of
diagnosis of brain metastases (P¼0.121), as well as the stage
of primary cutaneous melanoma (P¼0.5), were not significantly
associated with the overall survival. There were also no statistically
significant survival differences between the 5-year periods of
diagnosis of brain metastases: 1986–1990: 3.2 months (95% CI
2.8–7.6), 1991–1995: 5.6 months (95% CI 3.5–7.3), 1996–2000:
5.4 months (95% CI 4.2–7.3), 2001–2005: 5.6 months (95% CI
4.7–7.5), (P¼0.262).
A stepwise Cox multivariate analysis was performed to
determine the independent predictors of the overall survival. The
results of the multivariate analysis are shown in Table 2. The
independent prognostic factors of the overall survival were:
serum lactate dehydrogenase (Po0.001), administered therapy
(P¼0.002), number of brain metastases (P¼0.032) and presence
of bone metastasis (P¼0.044). CRT analysis identified three final
prognostic groups (Figure 1A). Group I comprised patients treated
with neurosurgery or stereotactic surgery. In group II were
included patients treated with WBRT or chemotherapy or
supportive therapy who had serum levels of serum lactate
dehydrogenase equal or less than two times the maximum normal
value. In group III were classified patients treated with WBRT or
chemotherapy or supportive therapy who had serum lactate
dehydrogenase more than two times the maximum normal value.
For each of these groups Kaplan–Meier survival curves were
computed and compared by means of log-rank test (Figure 1B).
Overall and pairwise, the three final groups were significantly
different with respect to survival (overall: Po0.001, group I vs II:
Po0.001, group I vs III Po0.001, group II vs group III: Po0.001).
Survival rates for each subgroup are shown in Figure 1. Group I
was the group with the most favourable prognosis with median
survival of 9.0 months, followed by group II (median survival 4.0
months) and group III (median survival 2.0 months). Comparing
the results of the recursive partition analysis (RPA) of the
Radiation Therapy Oncology Group (RTOG), and our CRT
analysis revealed significant different survival rates for both
methods. However, although the RPA allocates most of the
patients into class II, the CRT differs the patients into the three
prognostic groups more balanced (Table 3).
Table 2 Multivariate analysis of prognostic factors
HR (95%CI) P
a
Number of brain metastases
1 brain metastasis Ref 0.032
2 brain metastases 1.5 (0.9–2.5)
Multiple brain metastases 1.9 (1.2–3.2)
LDH
Normal range Ref o0.001
p 2 max normal 2.7 (1.8–4.0)
4 2 max normal 7.3 (3.7–14.3)
Presence of bone metastasis
No Ref 0.044
Yes 1.7 (1.0–2.8)
Administered therapy
Surgery Ref 0.002
SRS 1.0 (0.6–1.8)
WBRT 1.5 (0.9–2.5)
Chemotherapy 1.8 (0.9–3.4)
No therapy 5.4 (2.3–12.6)
Abbreviations: BM¼brain metastasis; CI¼confidence interval; HR¼hazard ratio;
SRS¼stereotactic radiosurgery; WBRT¼whole brain radiation therapy.
aSignificance
based on Wald test. Hazard ratio with its 95% confidence interval.
Brain metastasis
Neurosurgery or
SRS
- Group I -
WBRT/systemic/supportive
therapy
LDH 2 times the
upper normal
- Group II-
LDH >2 times the
upper normal
- Group III -
Prognostic group III II I
No. of patients 75 94 83
Median survival
months (95% CI)
4.0
(2.9–5.1)
9.0
(7.6–10.4
69:6 (92.0%)
52:23 (69.3%)
48:27 (64.0%)
20:55 (26.7%)
57:37 (60.6%)
30:64 (31.9%)
10:84 (10.6%)
80:14 (85.1%) 60:23 (72.3%)
49:34 (59.0%)
22:61 (26.5%)
9:74 (10.8%)
2.0
(1.5–2.5)
Karnofsky:
60%
70%
80%
90%
100%
1.3%
11.5%
9.0%
12.8%
65.4%
4.5%
15.7%
14.6%
22.2%
44.9%
10.7%
25.3%
12.0%
17.3%
34.7%
Extracranial met.
(yes : no)
—Pulmonalry
—Liver
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Figure 1 (A) Classification and regression tree analysis. Prognostic
groups were defined by means of the defining variables and the respective
median survival with its respective 95% confidence intervals. SRS:
stereotactic radiosurgery, WBRT: whole brain radiation therapy, LDH(s):
serum levels of lactate dehydrogenase. (B) Overall survival of patients with
brain metastasis from cutaneous melanoma by prognostic group (group I:
bold line, group II: broken line, group III: thin line). Overall and pairwise, the
three final groups were significantly different with respect to survival (log
rank Po0.001, group I vs II; Po0.001, group I vs III; Po0.001, group II vs III).
Brain metastasis in melanoma
M Staudt et al
1216
British Journal of Cancer (2010) 102(8), 1213–1218 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDISCUSSION
In this retrospective analysis, we aimed to identify determinants of
the outcome of patients with brain metastasis from cutaneous
melanoma. The overall survival of our patients was generally very
poor with median survival time not exceeding 5 months.
Comparable overall survival times have been shown by a few
other studies (Buchsbaum et al, 2002; Harrison et al, 2003; Fife
et al, 2004).
The results of our multivariate Cox analysis showed that the
main independent favourable prognostic factors in these patients
are the levels of serum lactate dehydrogenase (normal vs elevated),
the type of administered therapy (neurosurgery or SRS vs other),
the number of brain metastases (single vs multiple) and the
presence of bone metastasis (false vs true). By means of explorative
classification analysis, we identified three different prognostic
groups with statistically significant differences in the overall
survival. Patients treated with either neurosurgery or SRS
comprised the group with the most favourable prognosis. The
rest of the patients could be further sub-classified into two groups
based on the levels of serum lactate dehydrogenase (p2 upper
normal value vs 42 upper normal value).
This is the first study to identify different prognostic groups by
means of classification trees analysis in a relatively unselected
population of patients with brain metastases from melanoma
particularly by taking into account the levels of serum lactate
dehydrogenase, which is a well-established prognostic factor in
stage IV melanoma (Manola et al, 2000; Balch et al, 2001).
Normally serum lactate dehydrogenase is rising with increasing
tumour masses and can therefore be used as a surrogate marker
for tumour load (Agarwala et al, 2009). The use of recursive
partitioning analysis grouping, as described by the RTOG, has
been suggested as a tool for the stratification of patients with brain
metastases (Gaspar et al, 1997). However, this system does not take
into account particularities of different tumour types (like serum
lactate dehydrogenase levels for melanoma) and for this reason we
performed detailed analysis to identify more meaningful tools for
classification of patients according to their prognosis in our
population.
Our findings are in keeping with those of Sirott et al who
showed that in stage IV melanoma patients pre-treatment serum
lactate dehydrogenase level is associated with the overall survival
with a continuous rather than a discrete pattern. Increasing levels
of serum lactate dehydrogenase were associated with shorter
survival and the optimal cut-off point to identify different
prognostic groups was serum level of serum lactate dehydrogenase
exceeding double of upper normal value (Sirott et al, 1993). Taking
into account the short period of median survival of 2 months for
patients in group III we suggest being restrictive in applying
aggressive chemotherapy or WBRT because these patients seem
not to benefit.
Patients with brain metastasis usually receive multimodality
treatment including surgery, radiation therapy, chemotherapy, and
so on. In our sample, we identified 12 different therapy
combinations. To enable meaningful comparisons we created five
hierarchical groups of therapy. This classification was based
mainly on that conventional surgery and SRS were mutually
exclusive treatment modalities in our sample (data not shown),
which are related with significantly longer overall survival
compared with single treatment with WBRT, whereas systemic
therapy has not been shown to increase overall survival in patients
with brain metastasis from melanoma (Sampson et al, 1998;
Wronski and Arbit, 2000; Douglas and Margolin, 2002). The
overall survival did not differ significantly between patients treated
with neurosurgery or SRS, which is in line with the findings from
recent retrospective and one randomised study (Fife et al, 2004;
Aoyama et al, 2006; DiLuna et al, 2007). However, the indications
between direct surgery and SRS differ significantly and depend
mainly on the size, the number and the anatomical site of
metastatic lesions. These factors have a major effect on overall
survival of patients with brain metastases and until now there is no
randomised study between the two modes. As morbidity related
with neurosurgery, is much higher compared with SRS, it would be
of great importance to identify subgroups of patients who
might benefit equally from SRS compared with conventional
surgery. This could be ideally investigated in the frame of
randomised studies.
In our sample, more than half of the patients had less than three
brain metastases with 40% having single brain metastasis. Similar
results have been reported by Sampson et al (1998). Fine et al
reported a much lower rate of single brain metastasis (23%) (Fife
et al, 2004). However, in their study the rate of unknown cases was
50% that makes a valid comparison difficult. In addition, the
majority of our patients were asymptomatic and diagnosed by
brain scans performed during regular surveillance according to
national German guidelines (Orfanos et al, 1994; Garbe et al, 2006).
This approach is different compared with other countries such as
the United Kingdom or the United States where scans are only
performed in case of cerebral symptoms.
We found that a significant number of patients (17%) presented
without evidence of extracranial disease, whereas another 17% had
single organ extracranial involvement. These rates are much lower
compared with those reported by Sampson et al that might be
explained by selection of patients with more favourable prognostic
features to be referred to a neurosurgical department or by
underestimation of the true number of metastasis by early
generation CT or MRI as it was postulated by the investigators
(Sampson et al, 1998). In any case, a significant proportion of
patients with brain metastasis from melanoma, exceeding one-
third of the total in our sample, could be considered candidates for
local treatment with neurosurgery or SRS. The survival rates of
these patients are comparable with those reported for patients with
stage IV melanoma (Balch et al, 2001). This is a very interesting
finding, which argues against the general exclusion of patients with
brain metastases from large clinical studies in melanoma,
particularly in view of current evidence suggesting that che-
motherapy, which is active against extracranial metastasis may
also be effective against brain metastasis (Kaufmann et al, 2005;
Gerstner and Fine, 2007; Ranson et al, 2007).
In studies analysing medical outcomes over a long period of
time, data heterogeneity are always a concern. Improvement in
surgery and oncotherapy during a 17 years period might influence
the results of treatment of brain metastasis from melanoma.
However, when we analysed survival of sequential 5-year periods
no significant difference was evident. Our retrospective analysis
neither aimed nor had the strength to evaluate different
therapeutic modalities in the field of brain metastasis in
melanoma. This has to be investigated by means of targeted
prospective studies. Moreover, we did not analyse data regarding
administered therapies before diagnosis of brain metastasis and we
did not have information regarding specific complications of the
disease, which led to death. This would be of interest because
extracranial disease represents a major limitation on survival in
patients receiving focal treatment for melanoma brain metastasis
(Hasegawa et al, 2003). We did not have information on the
Table 3 Allocation of the patients into different prognostic groups
according to recursive partition analysis of the RTOG and CRT analysis
CRT I (%) CRT II (%) CRT III (%)
RTOG I 7.9 2.8 0.4
RTOG II 21.4 27.0 18.7
RTOG III 3.6 7.5 10.7
Abbreviations: CRT¼ classification and regression tree; RTOG¼Radiation Therapy
Oncology Group.
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snumber of SRS procedures received by the patients, which might
have an effect in the overall survival as it is recently suggested by a
retrospective study (Samlowski et al, 2007). In contrast, we had
detailed data with negligible rates of missing cases for most of the
variables we analysed and almost complete follow-up data for the
entire of our collective.
In conclusion, the prognosis of patients with brain metastasis
from cutaneous melanoma is ominous necessitating the
development of effective focal and systemic therapies. The
independent prognostic factors of these patients were the level of
serum lactate dehydrogenase, the administered therapy, the
number of brain metastases and the presence of bone metastasis.
On the basis of the administered therapy and the levels of serum
lactate dehydrogenase, three different prognostic groups with
statistically different overall survival could be identified. Patients
treated with conventional neurosurgery or SRS comprised the
group with the highest overall survival, which was comparable with
the overall survival of general stage IV melanoma patients; a
finding arguing against the exclusion of such patients from clinical
trials solely on the basis of dismal prognosis.
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